Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

481
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
481
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

574
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
574
Glaucoma: Overview01:25

Glaucoma: Overview

623
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
623

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intermediate Visual Performance of Clareon Versus Eyhance Enhanced Monofocal Intraocular Lenses.

Diagnostics (Basel, Switzerland)·2026
Same author

Ophthalmic and Visual System Changes in Human Spaceflight: A Review of Mechanisms, Measurement, and Countermeasures.

Journal of clinical medicine·2026
Same author

Clinical Outcomes and Complications After INTACS Implantation in Keratoconus: A Systematic Review.

Journal of clinical medicine·2026
Same author

Optical Coherence Tomography Biomarkers Predicting Progression to Atrophy in Non-Exudative Age-Related Macular Degeneration.

Diagnostics (Basel, Switzerland)·2026
Same author

Peripheral Hypertrophic Subepithelial Corneal Degeneration.

Journal of clinical medicine·2026
Same author

Prospective One-Year Outcomes of Preserflo MicroShunt Implantation in Glaucoma Following Keratoplasty.

Journal of glaucoma·2026

Related Experiment Video

Updated: Jul 23, 2025

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.2K

Microcyclophotocoagulation in Glaucoma Treatment: A Medium-Term Follow-Up Study.

Bartłomiej Bolek1, Adam Wylęgała2, Edward Wylęgała1

  • 1Chair and Clinical Department of Ophthalmology, School of Medicine in Zabrze, Medical University of Silesia in Katowice, District Railway Hospital, 40-760 Katowice, Poland.

Journal of Clinical Medicine
|July 14, 2023
PubMed
Summary

Transscleral microcyclophotocoagulation (µCPC) safely reduces intraocular pressure (IOP) in glaucoma patients over 18 months, though moderate success rates indicate a need for further research.

Keywords:
cyclodestructionglaucomamicrocyclophotocoagulationmicropulsetransscleral cyclophotocoagulation

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K
A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

19.6K

Related Experiment Videos

Last Updated: Jul 23, 2025

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.2K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K
A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

19.6K

Area of Science:

  • Ophthalmology
  • Glaucoma treatment
  • Surgical innovation

Background:

  • Glaucoma necessitates effective intraocular pressure (IOP) management.
  • Transscleral microcyclophotocoagulation (µCPC) is a treatment modality for glaucoma.
  • Long-term effectiveness and safety data for µCPC are valuable.

Purpose of the Study:

  • To evaluate the efficacy and safety of transscleral microcyclophotocoagulation (µCPC) in glaucoma patients.
  • To assess IOP reduction, medication use, and visual acuity over an 18-month period.
  • To determine the success rates and complication profile of µCPC.

Main Methods:

  • Prospective study involving 61 patients (64 eyes) with primary and secondary glaucoma.
  • µCPC procedure using a diode laser (FOX 810).
  • Primary outcomes: IOP reduction (≥20%), medication cessation, visual acuity; Secondary outcomes: complications. Measurements at multiple postoperative intervals up to 18 months.

Main Results:

  • Mean IOP reduced by 32.5% at the last follow-up (18 months), with statistically significant reductions at all time points (p < 0.001).
  • Qualified success rate was 38.5%; complete success (no medication) was 3.1%. 39.1% of eyes required retreatment.
  • Minor complications included hypotony (1.6%) and uveitis (3.1%); no other significant complications were noted.

Conclusions:

  • Transscleral microcyclophotocoagulation (µCPC) demonstrates safety and tolerability for medium-term IOP reduction in glaucoma.
  • The moderate success rates suggest that µCPC may be an adjunct or alternative treatment in specific cases.
  • Larger, randomized studies are recommended to validate these findings and optimize treatment protocols.